Formulation, Evaluation and Optimization of Fast dissolving tablet containing Tizanidine Hydrochloride

Similar documents
Formulation and Evaluation of Oro-Dispersible Tablets Containing Meclizine Hydrochloride

Research Article. Formulation and in-vitro evaluation of orodispersible tablets of olanzapine for the improvement of dissolution rate

Formulation and Optimization of Taste Masked Rapimelt Dolasteron Mesylate Tablets

FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF METOPROLOL TARTRATE WITH NATURAL AND SYNTHETIC SUPERDISINTEGRANTS

Scholars Research Library. Formulation and evaluation of Ketorolac Tromethamine fast dissolving tablets

Pharma Ingredients & Services. Ludiflash. Technical Information

Pelagia Research Library. Formulation and evaluation of fast dissolving sublingual tablets of amlodipine besylate

Formulation and in-vitro evaluation of pregabalin mini tablets for sustained release

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)

RESEARCH ARTICLE e-issn:

Formulation and Evaluation Of Metformin HCl Mouth Dissolving Tablet Using Sublimating Agent

Formulation and Evaluation of Ora-Solv Tablets of Pantoprazole Sodium

Radhika Parasuram Rajan et al. IRJP 2012, 3 (10) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Design and characterization of solid dispersion based fast dissolving tablet of Cetirizine hydrochloride

Formulation and Evaluation of Simvastatin Rapidmelts

Pelagia Research Library

FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS OF VALDECOXIB

Process validation of clopidogrel bisulphate 75 mg tablets

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

Direct compression of cushion layered ethyl cellulose coated extended release pellets into rapidly disintegrating tablets

OPTIMIZATION OF OLANZAPINE MOUTH DISSOLVING TABLETS USING MICRONIZATION

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

Formulation Design and Optimization of Orodispersible Tablets of Quetiapine Fumarate by Sublimation Method

FORMULATION AND EVALUATION OF POLYMER EFFECT ON in-vitro KINETICS OF SUSTAINED RELEASE MATRIX TABLETS OF CARVEDILOL USING MODEL DEPENDENT METHODS

Formulation and In-Vitro Evaluation of Sustained Release Tablet of Isosorbide -5- Mononitrate by Porous Osmotic Technology

Impact factor: /ICV:

FORMULATION AND EVALUATION OF ROFECOXIB LIQUISOLID TABLETS

OPTIMIZATION OF MELT-IN-MOUTH TABLETS OF LEVOCETIRIZINE DIHYDROCHLORIDE USING RESPONSE SURFACE METHODOLOGY

Pharma Silica Insights

Pelagia Research Library. Design fabrication and characterization of controlled released tablets of Trimetazidine di hydrochloride

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

NISSO HPC for Pharmaceutical Applications

Rajesh Kaza. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

Formulation of Fast-Dissolving Tablets of Promethazine Theoclate

Research Article. Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets

Formulation and Evaluation of Fast Dissolving Oral Films of Zolmitriptan

EUROPEAN JOURNAL OF European PHARMACEUTICAL. Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH.

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Research Article

World Journal of Pharmaceutical Research SJIF Impact Factor 5.990

INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES

Design and Evaluation of Sustained Release Tablets containing Solid dispersion of Ziprasidone hydrochloride

Studies in Prospective Process Validation of Gliclazide Tablet 80 mg Dosage Formulation

FORMULATION AND EVALUATION OF TRIHEXYPHENIDYL HYDROCHLORIDE TABLTES

Phulzalke S.B.,B A Kate, Bagade M. Y., Shete RV. Rajgad Dnyanpeeth s College of Pharmacy, Bhor, Pune

OSDrC OptiDose : A Revolution in Drug Formulation Technology

Design and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride

Parthiban Kakkatummal Nishad and Natesan Senthil Kumar

Pharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

Formulation Design and Optimization of an Enteric Coated Sustained Release Mucoadhesive Tablet of Metronidazole

Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components

Development and Characterization of Fast Dissolving Tablet of Diflunisal by Solid Dispersion Method

International Journal of PharmTech Research

RECENT TRENDS IN FORMULATION TECHNOLOGY FOR MOUTH DISSOLVING TABLET: AN OVERVIEW

DIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT

DOW AMBERLITE and DUOLITE Ion Exchange Resin Excipients

Formulation Design and Development of Mucoadhesive Tablets of Cefixime Trihydrate

Effect of Formulation and Process Variables

Functionalized Calcium Carbonate (FCC) FCC: Newly developed structured minerals as multifunctional excipients

Computation of Solubility parameters using Molecular. dynamics simulation

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

FORMULATION AND EVALUATION OF CLARITHROMYCIN IMMEDIATE RELEASE FILM COATED TABLETS

Physico-chemical comparison of famotidine tablets prepared via dry granulation and direct compression techniques

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

Formulation and Evaluation of Orodispersible Tablets of Granisetron Hydrochloride Using Agar as Natural Super disintegrants

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015

FORMULATION AND EVALUATION OF ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE TABLETS

COMPARATIVE EVALUATION OF TASTE MASKING METHODS OF ONDANSETRON HCl

Direct Compression Microcrystalline Cellulose Grade 12 versus Classic Grade 102

Design and Dosage Form. Dr. Deny Susanti

1. Master Batch Record Approvals Name Signature Date Originator

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets

RAJASHREE S. MASAREDDY*, GUPTA ALOKNATH L, DANISH KURIEN

THE PHARMA INNOVATION - JOURNAL Formulation and Development of Floating and Mucoadhesive Microspheres of Clarithromycin

Fabrication and in vitro evaluation of Venlafaxine Hydrochloride mini tablets filled hard Gelatin Capsules

A Review on Immediate Release Drug Delivery Systems

One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation

Roller Compaction: New trends, challenges and solutions

On-Demand Manufacturing of Pharmaceuticals

USP Hypromellose Phthalate

Module 3 Selection of Manufacturing Processes. IIT Bombay

FORMULATION OF TABLET CONTAINING CURCUMIN NANOEMULSION

IN VITRO COMPARATIVE SYUDY OF QUALITY CONTROL PARAMETERS OF SOME BRAND OF KETOROLAC TABLETS AVAILABLE IN BANGLADESH

Developing and Validating Dissolution Procedures for Improved Product Quality

Preparation of Cefpodoxime Proxetil - Polymeric Microspheres by the Emulsion Solvent Diffusion Method for taste masking

Design, evaluation and optimization of fluconazole trandermal patch by 2 2 factorial method

PLEASE SCROLL DOWN FOR ARTICLE

Process Validation And Risk Assessment Study of Loratadine Tablet

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action

Development of Sustain Release Matrix Tablet of Ranolazine Based on Methocel K4M CR: In Vitro Drug Release and Kinetic Approach

OPTIMIZED FORMULATION OF METOCHLOPRAMIDE ORALLY DISINTEGRATING TABLET. *Corresponding author: Samran,

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.9, pp , 2016

Formulation and Evaluation of Fast Dissolving Buccal Films Containing Zolmitriptan

Formulation And Evaluation Of Esomeprazole Magnesium Controlled Release Multiple Unit Matrix Pellets By Extrusion And Spheronization Technology

Formulation and Evaluation of Fast Dissolving Tablets of Paracetamol using Ocimum basilicum Seed Mucilage as Superdisintegrant

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

Development and Evaluation of Floating Drug Delivery System of Chlorothiazide

Transcription:

International Journal of PharmTech Research ISSN : 0974-4304 Vol.1,No.1,pp 34-42, Jan March 2009 Formulation, Evaluation and Optimization of Fast dissolving tablet containing Tizanidine Hydrochloride P.S. Zade, P.S. Kawtikwar *, D.M. Sakarkar Department of Industrial Pharmacy, Sudhakarrao institute of pharmacy, Pusad 445 204, M.S.,India. *Corres author: pskawtikwar@rediffmail.com Abstract: Tizanidine HCl is a centrally acting α-2 adrenergic agonist muscle relaxant. It is slightly bitter in taste. In the present study an attempt has been made to prepare bitterless fast dissolving tablet of Tizanidine Hydrochloride using Eudragit E 100 as a taste masking agent. Mass extrusion was the technique used for preparing taste masked granules. The tablet was prepared with three super disintegrants e.g. sodium starch glycolate, crosscarmellose sodium and crospovidone. The blend was examined for angle of repose, bulk density, tapped density and hausner s ratio. The tablets were evaluated for hardness, drug content and friability and disintegration time. The disintegration in oral cavity was also tested and was found to be 22 sec. Other tablets were prepared by using camphor as sublimating agent. It was concluded that tablets prepared by addition of superdisintegrant has less disintegration time than those prepared by sublimation method. Keywords: Fast dissolving tablet, Tizanidine HCl, Super disintegrating agents, Mass extrusion. Introduction and Experimental The concept of Fast Dissolving Drug Delivery System emerged from the desire to provide patient with conventional mean of taking their medication. Difficulty in swallowing (Dysphagia) is a common problem of all age groups, especially elderly and pediatrics, because of physiological changes associated with these groups of patients. Solid dosage forms that can be disintegrated, dissolved, or suspended by saliva in the mouth resulting in easy swallowing can provide significant benefits to the pediatric and geriatric population, as well as other patients who prefer the convenience of easily swallowable dosage forms. This tablet disintegrates instantaneously when placed on tongue, releasing the drug that dissolves or disperses in the saliva 1.

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 35 Tizanidine Hcl is chemically 3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-8-Thia-7,9- diazabicyclo [4.3.0] non a-2,4,6,9- tetraen-2-amine hydrochloride. It is a centrally acting α-2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, spastic diplegia 2. It is bitter in taste. Taste masking is an essential requirement for fast dissolving tablets for commercial success. Taste masking of the active ingredients can be achieved by various techniques. Two approaches are commonly utilized to overcome bad taste of the drug. The first includes reduction of drug solubility in saliva, where a balance between reduced solubility and bioavailability must be achieved. Another approach is to alter the ability of the drug to interact with taste receptor 3. Taste masked granules of bitter drugs can be prepared by using Eudragit E100 [cationic copolymer based on dimethyl amino ethyl methacrylate.] and ethanol. The extrusion technique represents a novel application of polymer processing technology to prepare pharmaceutical dosage forms. The process involves embedding a drug in a polymeric carrier while shaping the composite material to form a pharmaceutical product 4. In present study an attempt has been made to prepare taste masked granules of Tizanidine HCl. Taste masking of Tizanidine HCl was carried out by using Eudragit E 100 (Mass extrusion method). These taste masked granules or complex was further formulated into the mouth-dissolving tablet by direct compression method using sodium starch glycolate, crosscarmellose sodium and crospovidone as the superdisintegrants. Materials and Methods Tizanidine HCl was obtained as a gift sample from Blue Cross Pvt. Ltd. Nashik. Sodium starch glycolate, cross carmellose sodium, crospovidone and Eudragit E 100 were obtained as gift samples from Unichem Pvt. Ltd. Mumbai. Preparation of drug-eudragit e 100 taste masked granules by mass extrusion technique 4 : Fixed amount of drug was mixed with different amount of powdered Eudragit E 100 i.e. they were mixed at 1:1, 1:2, 1:3 and 1:4 ratios with the help of mortar and pestle. Then 10% ethanol was added to each mixture. Then gel was prepared using the mixture of the drug and Eudragit E 100 which was converted into the taste-masked granules by the extrusion method. The prepared gel was manually extruded (pressed out) using a syringe. After extrusion of the gel, ethanol was removed by evaporation overnight and subsequently the solidified gel in the shape of string was crushed into granules using a mortar.

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 36 Selection of drug-eudragit e 100 ratio: Four batches were prepared containing drug Eudragit E100 in the ratio of 1:1, 1:2, 1:3 & 1:4 in ethanol by the above-mentioned method. On the basis of the taste of the granules ratio 1:3 was finalized for further study. Physical evaluation of drug-eudragit e 100 granules:granules were evaluated for angle of repose, bulk density, tapped density, Hausner s ratio. Formulation of [bitterless] fast dissolving tablet of drug: Eudragit e 100 granules by disintegrant addition method. Fast dissolving tablets of Tizanidine HCl: Eudragit E100 granules were prepared using direct compression method after incorporating different superdisintegrants such as, crosscarmellose sodium (Ac-Di-Sol), crospovidone and sodium starch glycolate in different concentrations. Mannitol, Avicel PH 101 was used as directly compressible diluents. Nine formulations of Tizanidine HCl: Eudragit E100 granules were prepared and each formulation contained one of the three disintegrant in different concentration. Tablet weight was 125 mg; 8 mm punch was used for compression. Ingredient are depicted in table no. 1 Table 1: Formulation table of batch B1-B9. Ingredients (Quantity in B1 B2 B3 B4 B5 B6 B7 B8 B9 mg.) Granules (Equivalent to 4 mg of 18.18 18.18 18.18 18.18 18.18 18.18 18.18 18.18 18.18 Tizanidine Hcl) Mannitol 70.00 70.00 70.00 70.00 70.00 70.00 70.00 70.00 70.00 Avicel 101 PH 30.58 29.33 28.08 30.58 29.33 28.08 30.58 29.33 28.08 Crosscarmell ose Sodium 2.50 3.75 5.00 - - - - - - [Ac Di Sol] Sodium starch Glycolate - - - 2.50 3.75 5.00 - - - Crospovidone Aerosil Aspartame Tablet Weight - - - - - - 2.50 3.75 5.00 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.62 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 125 125 125 125 125 125 125 125 125

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 37 Evaluation of formulated tablet Tablet Hardness 5 The strength of tablet is expressed as tensile strength (Kg/cm 2 ). The tablet crushing load, which is the force required to break a tablet into halves by compression.it was measured using a tablet hardness tester (Pfizer Hardness Tester). Weight Variation Test 5 Weight variation test is done by weighing 20 tablets individually; calculating the average weight and comparing the individual tablet weight to the average. Friability 5 Friability test is performed to assess the effect of friction and shocks, which may often cause tablet to chip, cap or break. Roche friabilator was used for the Purpose. This device subjects a number of tablets to the combined effect of abrasion and shock by utilizing a plastic chamber that revolves at 25 rpm dropping the tablets at a distance of 6 inches with each revolution. Preweighed sample of tablets was placed in the friabilator, which was then operated for 100 revolutions. Tablets were dusted and reweighed. Compressed tablets should not loose more than 1% of their weigh. Content Uniformity 7 Five tablets were powdered and the blend equivalent to 4 mg of Tizanidine Hcl was weight and dissolved in suitable quantity of ph 1.2 solution. Solution was filtered and diluted and drug content analyzed spectrophotometrically at 228 nm. Disintegration Time 5 The disintegration time of tablet was measured in water (37 0 C) according to USP disintegration test apparatus. Three trials for each were performed Wetting Time 6 The method reported by Yunixia et.al.was followed to measure tablet-wetting time. A piece of tissue paper folded twice was placed in a small petry dish (ID6.5cm) containing 6ml of ph6.8 (simulated saliva fluid). A tablet was put on the paper and the time for complete wetting was measured. Three trials for each were performed. Data revealed in table no. 2 In-Vitro Release Profile of Formulated Tablets The dissolution of Tizanidine HCl tablets was carried out in basket type dissolution apparatus. The dissolution medium was 900 ml of gastric simulated fluid (without enzyme) ph 1.2 maintained at 37 0 C+ 1 0 C. The basket was rotated at 50 rpm for 20 min. The sample of 10 ml was withdrawn after every 5 min. and its absorbance was measured at 228 nm.

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 38 Table 2: Evaluation of batch B1-B9 and C1-C3 Form ulatio n Hardne ss (kg/cm 2) ±S.D B1 3.13± 0.005 B2 3.46± B3 4.00± B4 3.76± 0.005 B5 3.96± B6 4.03± B7 3.96± B8 4.03± B9 4.06± 0.005 C1 4.4± C2 3.1± 0.005 C3 3.4± Fria bility (%) Weight variatio n Test Wetti ng time( sec) ±S.D Thickne ss (mm) ±S.D 0.44 Passes 46.66 ±0.03 2.24±0.0 1 0.28 Passes 39.66 2.22±0.0 ±0.02 1 0.2 Passes 22.66 2.20±0.0 ±0.05 2 0.48 Passes 40.66 2.21±0.0 ±0.03 05 0.36 Passes 36.33 2.21±0.0 ±0.05 2 0.28 Passes 22.00 2.20±0.0 ± 1 0.52 Passes 43.33 2.22±0.0 ±0.06 3 0.24 Passes 34.33 ±0.05 2.20±0.0 05 0.16 Passes 19.66 ±0.06 2.19±0.0 1 0.15 Passes 3.15± 0.06 (min) 1.96 Passes 2.20± 0.05 (min) 0.96 Passes 2.0±0.05 (min) 2.21±0.0 05 2.24±0.0 1 2.22±0.0 3 Drug Content (%) Disintegr ation time(sec) 99.95 30.33± 99.00 20.66± 101.21 10.66± 0.02 100.50 20.66±0.0 05 100.07 16.00± 0.02 98.95 12.22± 99.90 23.66± 100.12 15.66±0.0 05 101.10 10.33± 99.95 2.35± 100.25 1.68± 0.02 100.12 1.31± 0.02 Optimization of Formula From the above formulations the optimized formula from Drug: Eudragit E100granules; tablets was selected, depending upon the several factors such as less disintegrant concentration, less disintegration time and fast dissolution rate. Dissolution profile given in figure no. 1

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 39 Figure No. 1: Dissolution profile of batch B9 (disintegrant addition method). Stability Studies The stability studies of formulated tablets were carried out at 40 0 C and 75% RH using a stability chamber for one month. The effects of temperature and time on the physical characteristics of the tablet were evaluated for assessing the stability of the prepared formulations. The different parameters that were studied are disintegration time, hardness, friability, drug content and dissolution rate. Formulation of [bitterless] mouth dissolving tablet of drug: Eudragit E 100 granules by sublimation method 8. The second approach used in the preparation of fast dissolving tablet of Tizanidine Hcl-Eudragit E 100 granules was sublimation method. In this study mouth-dissolving tablet was prepared by using camphor in different ratios, as it sublimes readily. Camphor, which was used as a subliming agent, is nontoxic. Three formulations of drug Eudragit E100 granules containing camphor in different proportions were prepared by using mannitol as a diluent. It was compressed on single punch tablet machine using 8 mm punches to get tablet of 130 mg weight. Evaluation of tablet 5, 9. Tablets prepared by sublimation method were evaluated for weight variation, hardness, content uniformity, wetting time, disintegration time, friability and in-vitro dissolution test. Dissolution profile of optimized batch given in figure no. 2 Comparison of tablets prepared by disintegrant addition and sublimation method. The tablets prepared by both method i.e. disintegrant addition and sublimation method were compared using different parameters like in-vitro disintegration time, wetting time, friability and % drug release.

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 40 Figure No. 2: Dissolution of batch C3 (sublimation method). Results and Discussion Eudragit E100 was selected for the taste masking of Tizanidine Hcl. The taste-masked granules of drug and Eudragit E100 were prepared by simple mass extrusion technique using syringe. The drug content was found to be 88% in the granules. The physical properties like bulk density, angle of repose and the shape of complex was found to be 0.7843 g/cm 3, 27.54 0 and irregular respectively, Hausner s ratio was found to be 1.02. Above data indicate granules have good flowability. Nine formulations of drug Eudragit E100 granules (B1-B9) were prepared by varying the concentration of superdisintegrant. Tablets were prepared using direct compression. Tablets were obtained of uniform weight due to uniform die fill, with acceptable weight variation as per pharmacopoeial specification. The drug content found in the range of 98.95-101.21% (acceptable limit) and the hardness of the tablet was found between 3.13-4.06 kg/cm 2. The tablet thickness was found to be 2.19-2.24 mm, friability of tablet was found below 1% indicating good mechanical resistance. The wetting time of formulated tablets was found in the range of 19.66-46.66 sec and disintegration time of all batches was found in the range of 10.33-30.33 sec. Batch B-9 was selected as optimized batch containing crospovidone as super disintegrant in 5% concentration. It has less disintegration time of 10.33 sec. The dissolution study was carried out and 100.57% of drug release was occurring within 20 min. The stability study of optimized batch was carried out at 40 o C-75% RH. The tablets were found to be stable at such condition and other parameters were found to be unaffected. On the other hand tablets formulation prepared with camphor (10%, 20%, 30%), the formulation C3 was chosen. This formulation disintegrated faster, 1.31 min., compared to C1 and C2 which showed disintegration time of 2.35 min. and 1.68 min. Hardness of all formulation was found in the range of 3.1-4.4 kg/cm 2. All

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 41 formulation passed the weight variation test. The wetting time of all formulation was found in the range of 2-3.15 min. The percent drug release was found to be 100.15% in 25 minutes. The friability problem occurs with the formulation prepared by sublimation method, tablets were more friable, the friability of batch C3 was found to be 0.96%. Both formulation i.e. B9 & C3 showed good bioavaibility. The formulation B9 was found to be best as this formulation showed less disintegration time, good hardness, short wetting tine and good content of active ingredient. Comparison of tablets prepared by superdisintegrants addition and sublimation method revealed that superdisintegrant addition method was superior to sublimation method. It was concluded that fast dissolving tablet of Tizanidine Hcl can be successfully prepared by super disintegrant addition and sublimation method and super disintegration method was found to be superior to that of sublimation method. Taste masking with Eudragit E 100 was also found to be effective. References 1) S. S. Biradar, S. T. Bhagavati, I. J. Kuppasad: Fast Dissolving Drug Deliver Systems: A Brief Overview. The Internet Journal of Pharmacology. 2006. Volume 4 Number 2. 2) Ikunobu Muramatsu and Shigeru Kigoshi Tizanidine may discriminate between Imidazoline-receptor and ά-2 adrenoceptor Japan jour. Pharmacology, 1992, 59-457-459. 3) Brahmankar D. M., Jaiswal S.B., Biopharmaceutics & Pharmaceutics ; First Edition, 1995, PP 335 4) Watanabe Y., Ishikawa Y., Utoguchi N. and Matsumoto M., Preparation and evaluation of tablets rapidly disintegrating in saliva containing bitter taste masked granules by the compression method, Chem. Pharm. Bull., 1999, 47, PP 1451-1457. 5) Sreenivas S. A, Gadad A. P Formulation and evaluation of Ondancetron Hcl directly compressed mouth disintegrating tablets. Indian Drugs, 2006, 43(1),:35-38, 6) Devarajan, Sivasubramanian, Lakshmi Simultaneous spectrophotometer determination of Valdecoxib and Tizanidine in tablets Indian J Pharm Sci; 2006.68:240-242.

P.S. Kawtikwar et al./int.j. PharmTech Res.2009,1(1) 42 7) Adel M. Aley, M. Semreen and Mazin K. Qato To produce rapidly disintegrating Tenoxicam tablet via Camphor sublimation. Pharmaceutical Technology, 2005, 68-78. 8) Koizumi K., WatanabeY., Morita K., Utoguchi N. and Matsumoto M.; New method of preparing high porosity rapid saliva soluble compressed tablet using mannitol with camphor, a subliming material, Int. J. Pharm. 1997, 152, PP 127-131. 9) Ishikawa T., Kuizumi N., Mukai B., Utoguchi N., Fujii M., Matsumoto M., Endo H., Shirrotake S. and Watanabe Y., Preparation of rapidly disintegrating tablet using new types of microcrystalline cellulose (PH M series) and L-HPC by direct compression method, Chem. Pharm. Bull., 2001, 49, PP 134-139 Acknowledgement Authors are thankful to Blue Cross Pvt. Ltd., Nasik for providing drug sample of Tizanidine hydrochloride. *****